Pharma giants see huge potential in new "super technology" for fighting a wide range of diseases

Two successful Covid-19 vaccines are just the start for mRNA technology.

Morten Søgaard Vice President and Head, Genome Sciences & Technologies, Worldwide R&D at Pfizer | Photo: Jens Panduro

It has already provided the world with two highly-effective corona vaccines with limited side effects. However, this is just the beginning for mRNA technology, industry players say.

"I believe that the low-hanging fruit will be within infectious diseases. We have shown that the technology works really well, when it is injected into muscle, and it provides both antibodies and a t-cell response. It is working very well with Covid-19 and we are currently investigating its potential within other infections diseases," says Morten Søgaard, Vice President and Head of Genome Sciences & Technologies, Worldwide R&D at Pfizer.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs